Codix Group Secures WHO Approval for Local Packaging of HIV Diagnostic Test in Nigeria
Codix Group, a subsidiary of Colexa Biosensor Ltd, has been granted approval by the World Health Organization (WHO) to package a WHO Prequalified Rapid Diagnostic Test (RDT) kit at its facility in Nigeria. This significant endorsement allows Colexa Biosensor to produce the WHO Prequalified HIV Rapid Diagnostic Test locally, enhancing the country’s healthcare landscape.
In an announcement made by Codix Group on Wednesday, the company underscored the importance of this milestone, which positions Nigeria as a pivotal contributor to healthcare production capabilities and bolsters access to critical diagnostic tools. The Standard Q HIV 1/2 Ab 3-Line Test has now become the first WHO Prequalified HIV RDT to receive packaging approval within Africa, representing a historic achievement for the continent.
The statement emphasized that this accomplishment is a testament to the company’s commitment to bolstering Nigeria’s healthcare infrastructure and aligning with the President’s vision of promoting local manufacturing and innovation. Since the factory’s commissioning in December 2023, Colexa Biosensor has garnered recognition from various global health bodies, including WHO, Global Fund, UNITAID, FIND, and PEPFAR. The operational capacity of the facility marks a vital step in reducing import dependence, enhancing access to high-quality In-Vitro Diagnostics (IVDs), and nurturing Nigeria’s healthcare value chain.
Moreover, the approval opens new avenues for procurement by Nigeria and international donors, further amplifying efforts to combat HIV on both local and global fronts. Codix Group expressed pride in reaching this milestone and reaffirmed its dedication to raising healthcare standards across Nigeria and beyond.
This achievement is anticipated to encourage further investment in local healthcare manufacturing, signaling a promising future for the industry across Africa.
Join our Channel...